Drug Profile
Research programme: Alzheimer's disease immunotherapy - Emergent BioSolutions/University of British Columbia
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Cangene Corporation
- Developer Emergent BioSolutions; University of British Columbia
- Class
- Mechanism of Action Amyloid beta-protein inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Alzheimer's-disease in Canada (Parenteral)
- 21 Feb 2014 Cangene Corporation has been acquired and merged into Emergent BioSolutions
- 21 Feb 2013 Early research is ongoing in Canada